MEDICINOVA, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MEDICINOVA, INC. (MNOV) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-10
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $42.28K, a 69.58% decline from fiscal 2023.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $139.00K.
- MEDICINOVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $870.37K, a 409.42% increase from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $42.28K 10-K · filed 2026-03-10 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $42.28K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $42.28K 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $139.00K 10-K · filed 2025-02-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $139.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $139.00K 10-Q · filed 2024-08-08 | |||
| 2021-12-31 | -$5.14K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-28 | $693.96K derived: sum of 2 quarters · filed 2023-03-28 | $870.37K 10-K/A · filed 2023-03-28 | |
| 2021-09-30 | $699.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $875.51K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $176.42K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $170.86K 10-K · filed 2022-02-16 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $31.88K derived: sum of 2 quarters · filed 2021-02-19 | $185.00K derived: sum of 3 quarters · filed 2021-02-19 | $534.61K 10-K · filed 2021-02-19 |
| 2019-09-30 | $31.88K 10-Q · filed 2019-10-24 | $185.00K derived: sum of 2 quarters · filed 2019-10-24 | $534.61K 10-Q · filed 2019-10-24 | |
| 2019-06-30 | $153.13K 10-Q · filed 2019-07-25 | $502.73K 10-Q · filed 2019-07-25 | ||
| 2019-03-31 | $349.60K 10-Q · filed 2019-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |